Lipedema is an underdiagnosed chronic debilitating disease characterized by bruising, pain and excess subcutaneous fat affecting the lower and/or upper limbs of women during or after periods of hormonal change, especially puberty ([@ref1]). The first guidelines on lipedema were proposed in Germany in 2015, and again in 2017 using the international classification of function, disability and health ([@ref2]-[@ref4]). Lipedema can easily be confused with obesity, but is distinguished by primarily affecting the lower limbs and upper extremities; the fat deposits do not reduce with a low-calorie diet and body mass index is normal ([@ref5]). Lipedema can also be confused with lymphedema, but is always bilateral, whereas lymphedema can be unilateral or bilateral; pain and bruising are absent in lymphedema while lipedema patients are negative for Stemmer sign ([@ref6]). The prevalence of lipedema has been reported to be 1-9/100,000 ([@ref7]). Lipedema can be considered a component of a spectrum of diseases characterized by dysregulated proliferation of adipose tissue and pain: generalized diffuse form of Dercum disease (painful pearl-sized nodular subcutaneous adipose tissue throughout the body); generalized nodular form of Dercum disease (large painful nodules on the arms, trunk, and thighs); lipedema (localized form of painful fat with pearl-sized nodular fat and larger masses on the limbs); localized nodular form of Dercum disease (localized around joints); Madelung disease or multiple symmetric lipomatosis (nodular fat and lipomas on the upper part of the body ([@ref8],[@ref9]). Genetic testing that includes all genes known to be involved in syndromes with localized accumulation of subcutaneous fat is useful for confirming diagnosis, and for differential diagnosis, recurrence risk evaluation and prenatal diagnosis in families with a known mutation ([@ref10]).

Syndromes with localized subcutaneous fat accumulation can have autosomal dominant or autosomal recessive inheritance ([Table 1](#T1){ref-type="table"}). Pathogenic variants may be missense, nonsense, splicing or small indels. MAGI uses a multi-gene NGS panel to detect nucleotide variations in coding exons and flanking introns of the genes listed in [Table 1](#T1){ref-type="table"}.

###### 

Genes associated with various forms of localized accumulation of subcutaneous fat

  Gene         OMIM gene   Disease                                                                          OMIM disease     Inheritance   Function
  ------------ ----------- -------------------------------------------------------------------------------- ---------------- ------------- --------------------------------------------------------------------------------------------------------------
  *POU1F1*     173110      Combined pituitary hormone deficiency 1 (1 family with lipedema)                 613038           AD            Regulation of expression of growth hormone, prolactin, thyroid-stimulating hormone
  *NSD1*       606681      Sotos syndrome 1 (1 case with lipedema)                                          117550           AD            Androgen receptor transactivation
  *ALDH18A1*   138250      Cutis laxa, type III (abnormal fat pad, buttocks, upper thighs (some patients)   616603, 219150   AD, AR        De novo biosynthesis of proline, ornithine, arginine
  *PALB2*      610355      Multiple subcutaneous familial lipomatosis (1 case)                              /                AD            DNA repair
  *TBL1XR1*    608628      Pierpont syndrome                                                                602342           AD            Essential transcription activation mediated by nuclear receptors
  *MFN2*       608507      Madelung disease                                                                 151800           AR            Mitochondrial membrane protein necessary for mitochondrial fusion and maintenance of mitochondrial network
  *LMNA*       150330      FPLD2                                                                            151660           AD            Nuclear assembly, chromatin organization, nuclear membrane and telomere dynamics
  *PPARG*      601487      FPLD3                                                                            604367           AD            Master regulator of adipocyte differentiation
  *PLIN1*      170290      FPLD4                                                                            613877           AD            Coating of lipid storage droplets in adipocytes
  *CIDEC*      612120      FPLD5                                                                            615238           AR            Regulation of lipid droplet enlargement by restricting lipolysis, favoring storage
  *LIPE*       151750      FPLD6                                                                            615980           AR            Hydrolysis of stored triglycerides to free fatty acids
  *AKT2*       164731      FPLD                                                                             /                AD            Key-mediator of insulin receptor
  *ADRA2A*     104210      Atypical FPLD                                                                    /                AD            Fundamental for regulation of neurotransmitter release from sympathetic nerves and adrenergic neurons in CNS

FPLD=familial partial lipodystrophy; AD=autosomal dominant; AR=autosomal recessive; CNS = central nervous system.

Conclusions {#sec1-2}
===========

We created a NGS panel to detect nucleotide variations in coding exons and flanking regions of all the genes associated with localized accumulation of subcutaneous fat. When this suspects is present we perform the analysis of all the genes present in this short article.

In order to have a high diagnostic yield, we developed a NGS test that reaches an analytical sensitivity (proportion of true positives) and an analytical specificity (proportion of true negatives) of ≥99% (coverage depth ≥10x).
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